drugset / Trial / NCT01159769

Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis

NCT01159769

Phase 4 Completed 215 enrolled Alcon Research
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.

Timeline

Start
2010-06
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Olopatadine Other / unclassified 0.2 % Other

Indications